 Home > Encyclopedia > Acipimox

Acipimox

Acipimox structure

CAS No:
51037-30-0
Formula:
C6H6N2O3
Chemical Name:
Acipimox
Synonyms:
2-Pyrazinecarboxylic acid,5-methyl-,4-oxide;Pyrazinecarboxylic acid,5-methyl-,4-oxide;Acipimox;5-Methylpyrazinecarboxylic acid 4-oxide;5-Methylpyrazine-2-carboxylic acid 4-oxide;Olbetam;Olbemox;K 9321
Categories:
Active Pharmaceutical Ingredients > Circulatory System Drugs

Description

Acipimox is a niacin derivative used as a hypolipidemic agent.Target: Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administrat

5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid.|Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.|Acipimox is a niacin derivative and nicotinic acid analog with activity as a hypolipidemic agent. Acipimox has special application for the treatment of hyperlipidemia in non-insulin-dependent diabetic patients.

Acipimox Basic Attributes

Molecular Weight：

154.12

Exact Mass：

154.12

EC Number：

256-928-3

UNII：

K9AY9IR2SD

NSC Number：

759818

DSSTox ID：

DTXSID2046202

NCI Thesaurus Code：

C72982

ATC Code：

C10AD06|C - Cardiovascular system

HScode：

2933990090

Characteristics

PSA：

75.6

XLogP3：

-1

Appearance：

low yellow liquid or crystalline

Density：

1.4±0.1 g/cm3

Melting Point：

178.5 °C

Boiling Point：

539°C at 760 mmHg

Flash Point：

279.8±28.7 °C

Refractive Index：

1.608

Storage Conditions：

2-8°C

Toxicity：

LD50 orally in mice: 3500 mg/kg (Ambrogi)

Safety Information

Transport codes：

NONH for all modes of transport

wgk germany：

hazard class code：

safety instructions：

RTECS Number：

UQ2453000

Marks：

Precautionary statement(s)：

P305 + P351 + P338

Hazard Statements：

H319

GHS Classification：

|Warning|H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]|P264, P280, P305+P351+P338, and P337+P313|Aggregated GHS information provided by 71 companies from 2 notifications to the ECHA C&L Inventory.

Drug Information

Drug Indication：

Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).

MeSH：

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)

Mechanism of Action：

Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.

MeSH Entry Terms：

5-methylpyrazine-2-carboxylic acid 4-oxide

Acipimox Use and Manufacturing

Antilipemic.

Computed Properties

Molecular Weight:154.12
XLogP3:-1
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:1
Exact Mass:154.03784206
Monoisotopic Mass:154.03784206
Topological Polar Surface Area:75.6
Heavy Atom Count:11
Complexity:162
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Material

Maleic anhydride

Hydrogen peroxide

Drug Function and Efficacy

Acipimox is a derivative of nicotinic acid, which can inhibit the decomposition of adipose tissue, reduce the release of free fatty acids from adipose tissue, thereby reducing the synthesis of triglycerides (TG) in the liver, and by inhibiting the synthesis of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), the concentration of triglycerides (TG) and total cholesterol (TC) in the blood decreases. This product can also inhibit the activity of liver lipase and reduce the decomposition of high-density lipoprotein (HDL).

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Pemetrexed disodium
Ingredients	Acipimox
Manufacturer	Nanjing Pharmaceutical FACTORY Co., Ltd.

Pemetrexed disodium
Ingredients	Acipimox
Manufacturer	Nanjing Asia-East Sunrise Pharmaceutical Co., Ltd.

Acipimox Capsules
Ingredients	Acipimox.
Indication	If overdose toxicity is observed, monitoring and systemic supportive care should be administered.
Specifications	0.25g
Manufacturer	Di'ao Group Chengdu Pharmaceutical Co., Ltd.

See More Related Drugs

Registered Holders

Lunan Pharmaceutical Group Corporation

China
Active
Shandong Newtime Pharmaceutical Co., Ltd.

China
Active
Lunan BETTER Pharmaceutical Co., Ltd.

China
Active

See More Registered Holders

Recommended Suppliers of Acipimox

Wuhan Pnq Int Trade Co., Ltd Contact Supplier

CN
3 YRS

Business licensed

Trader Supplier of Apigenin,PQQ,NMNH

API 99% Acipimox CAS 51037-30-0 Pharmacy Grade

Unit Price: $5.15-6.18 /G FOB

CAS No.: 51037-30-0

Grade: Chemical Grade

Content: 99%

Inquiry
HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Acipimox

CAS No.: 51037-30-0

Content: 99.00%

Inquiry